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Summary We have investigated the influence of tumour cell DNA content (ploidy) on survival of 416
patients undergoing excisional surgery for colorectal cancer. Two hundred and eleven (51%) tumours had an
abnormal DNA content (aneuploid or tetraploid). There was no correlation between ploidy status, sex, age
and pathological stage, histological grade, tumour site, local tumour extension or assessment of curability.
Patients with tumours with an abnormal DNA content had a poorer survival 68/211(32%) than patients with
near normal (diploid) DNA content 88/205 (43%) (test statistic 5.0, P = 0.02). The patient subgroups in which
DNA content exerted an influence on survival were: stage B tumours (P = 0.058), moderately differentiated
tumours (P = 0.004), rectal tumours (P = 0.02), and mobile tumours (P = 0.02). Multivariant analysis showed
that pathological stage, local tumour extension and DNA ploidy were all independent prognostic indicators
whereas histological grade, tumour site and assessment of 'curability' were not. The influence of pathological
stage, however, was much greater than that of local tumour extension or DNA ploidy. Tumour cell DNA
content together with pathological stage and local tumour extension may be used in a prognostic index and
may be important in planning adjuvant therapy.
At the present time there is general agreement that the most
powerful prognostic information in patients with large bowel
cancer is given by the extent of tumour spread. In general,
the staging system used is that proposed by Dukes (1932)
with or without the modifications suggested by Kirklin et al.
(1949) and Astler and Coller (1954). Recently a staging
system has been suggested by Jass et al. (1987) which adds an
assessment of peritumoral lymphocytic infiltration to the
more traditional parameters of local tumour spread and
lymph node status. Although Jass's system tends to increase
the number of patients in whom a confident prediction of
outcome may be made, this and the other systems tend to
leave a large group of patients in an intermediate group, for
example Dukes's stage B. While we know that patients with
stage A tumours will generally do well and those with liver
metastases (stage D) will tend to fare badly, the fate of those
patients in the intermediate group is less certain. Other
parameters have been suggested which may help to define
prognosis. Histological grade has been shown to give prog-
nostic information (Phillips et al., 1984) but tends to be
subjective with wide variation in grading between observers
(Blenkinsopp et al., 1981) and a tendency for the majority of
tumours to be graded as moderately differentiated, reducing
the discrimination of this particular parameter. Tumour cell
DNA content can be rapidly and easily measured using flow
cytometry either in fresh tissue (Quirke et al., 1985) or in
paraffin-embedded material (Hedley et al., 1983). It gives a
quantitative means of distinguishing between tumours with a
DNA diploid or near normal compliment of chromosomal
material and those with a DNA aneuploid or abnormal
amount of DNA. The first demonstration that this may be of
value in the prognosis of colorectal cancer was by Wolley et
al. in 1982 and there have been a number of reports subse-
quently showing that patients with tumours with an aneu-
ploid DNA content have a worse survival than those with
diploid or near diploid DNA content (Quirke et al., 1987;
Scott et al., 1987; Goh et al., 1987; Kokal et al., 1989). In
1985 we reported a series of 134 patients and showed that
tumour cell DNA content was an independent prognostic
variable in colorectal cancer (Armitage et al., 1985). We have
continued this work to measure tumour cell DNA content in
a sufficient number of patients to allow useful subgroup
analysis.
Patients and methods
Patients were identified from a survey of patients with colo-
rectal cancer treated at the Nottingham General Hospital
between 1969 and 1977 and formed part of a larger group of
over 1,000 patients reported by Stower & Hardcastle (1985).
The patients included were all those having resections
between 1973 and 1977, for whom tumour blocks could be
found from the pathology archives except for patients with
stage A tumours where all available patients were included
(1969-77), in order to give a larger subgroup for analysis.
The survival of each patient was known with at least 5-year
follow-up, this being taken from hospital records, the family
doctor records and the Trent Regional Cancer Registry.
Uncorrected survival has been used as, in a retrospective
study, a standard end-point needs to be defined. Two groups
of patients were excluded, those on whom no resection was
performed since no tissue would be available for study and
those who died in the immediate postoperative period when
it is unlikely that tumour cellular factors would influence
outcome. In addition to survival, the other factors which
were known were tumour site, pathological stage and histo-
logical grade. Local tumour extension and surgeon's estima-
tion of curability had been assessed retrospectively from the
case records in the larger series repiorted by Stower & Hard-
castle (1985) and were also available for analysis.
The method of DNA staining was essentially that described
by Hedley et al. (1983). Sections of 20 gsm were cut from
paraffin-embedded material, consistent with our previous
report. A single block containing a representative sample of
tumour was analysed. Sections were dewaxed with xylene,
rehydrated through serial alcohols before being washed in
water. They were disaggregated using 1 ml of 0.5% pepsin
(Sigma Chemical Co., St Louis, MO, USA) in 0.9% NaCl
adjusted to pH 1.5. After digestion the samples were filtered,
washed and resuspended in 1 tsgml-I 4,6-diaminido-2-phen-
ylindole dihydrochloride (DAPI) (Boehringer Corporation,
London) for 30 min at room temperature. A fuller descrip-
tion of this method is included in a previous publication
(Armitage et al., 1985). The tumour cell DNA content was
measured using a FACS IV cell sorter (Becton Dickinson
FACS Systems, Sunnyvale, CA, USA). Ultra-violet excitation
was used at 350 and 360 nm and the fluorescence collected
via a band pass filter at 488 nm. Between 10,000 and 50,000
cells were analysed and a histogram derived. The fluorescence
intensity of each peak (channel number) was measured and
the DNA index was calculated. The DNA index is the
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fluorescence intensity (DNA content) of the tumour cell Gl/0
peak divided by the fluorescence intensity (DNA content) of
the 'normal' Gl/0 cell peak (Hiddeman et al., 1984). Where
there was no separate abnormal tumour cell peak the two
peaks would coincide giving a DNA index of 1. Where there
was a separate abnormal tumour cell peak (aneuploid) this
was only taken to be present when it contained at least 10%
of the total counted cells within this peak. Tumours were
classified as tetraploid where the DNA index was between 1.9
and 2.1 and there were 15% or more of the total cells within
the peak. In some aneuploid and tetraploid tumours the
number of these cells as a percentage of the whole was
calculated and expressed as a percentage aneuploid. The
mean percentage coefficient of variance (CV) for the diploid
Gl/0 peaks was 7.7 1.54 (n =47) and for the aneuploid
Gl/0 peaks was 6.4 1.61 (n= 27).
The correlations between DNA index and the clinical and
pathological features were made by the x2 test, survival
analysis and multi-variant analysis was done using the
BMDP package PIL and PLR respectively (BMDP Statis-
tical Software Inc., Los Angeles, CA, USA).
Results
The tumour cell DNA content was measured in tumours
from 416 patients. In total, 211 (51.3%) tumours had an
abnormal (aneuploid and tetraploid) DNA content and 205
(48.7%) had a near normal (diploid) DNA content. The
relationship to sex, age, pathological stage, histological
grade, tumour site, local tumour extension and curability are
shown in Table I. For tumour site, the right side of the colon
has been taken as proximal to the splenic flexure and the left
side between splenic flexure and the rectum including the
rectosigmoid region. There was no significant correlation of
DNA content with any of these variables.
There was a survival advantage to those patients with
diploid tumours with 88/205 (43%) surviving 5 years com-
pared with 68/211 (32%) patients with aneuploid tumours
(test statistic (Mantel-Cox) 5.0, 1 d.f., P = 0.02) (Figure 1).
The data were subjected to subgroup analysis on the basis of
pathological stage, histological grade, tumour site, local tu-
mour extension, assessment of curability and age. The results
are shown in Table II. The subgroups in which tumour cell
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Figure 1 Survival curves for patients with diploid and aneuploid
tumours.
DNA had an influence on survival were: stage B tumours,
moderately differentiated tumours, rectal tumours, mobile
tumours and patients less than 70 years old. Sixteen tumours
(3.9%) were classified as tetraploid. There was no difference
in 5-year survival in patients with these tumours (5/16 (31%)
surviving) compared with those with aneuploid tumours (63/
195 (32%) surviving). They have therefore been considered
with aneuploid tumours. Percentage ploidy was calculated for
91 aneuploid or tetraploid tumours. In patients with these
tumours there was no difference in survival whether sub-
groups were analysed using cut-off points of 20%, 30% or
40% aneuploidy. In order to ascertain whether tumour cell
DNA content, as a prognostic indicator was independent of
the other factors the data were subjected to multivariate
analysis using stepwise logistic regression. A summary of this
is shown in Table III. It can be seen that when considered
individually, the factors which were discriminatory were
pathological stage, histological grade, DNA index and cura-
bility and local tumour extension. However, when considered
Table I Relation of DNA content to clinical and pathological
parameters
DNA content
Aneuploidl
Pathological stage tetraploid Diploid
A 21 (50%) 21 (50%)
B 86 (48%) 93 (52%)
C 67 (51%) 64 (49%)
D 37 (58%) 27 (42%)
Overall 211 (51%) 205 (49%)
Histological grade
Well differentiated 77 (52%) 72 (48%)
Mod. differentiated 109 (51%) 103 (49%)
Poor differentiated 25 (50%) 25 (50%)
Tumour site
Right side 45 (48%) 48 (52%)
Left side 72 (52%) 67 (48%)
Rectum 94 (51%) 90 (49%)
Local extension
Mobile 86 (50%) 87 (50%)
Local extension 123 (51%) 116 (49%)
Curability
Curative 103 (50%) 105 (50%)
Non-curative 108 (52%) 100 (48%)
Sex
Male 106 (52%) 99 (48%)
Female 105 (50%) 106 (50%)
Age
< 70 years 137 (51%) 133 (49%)
>70 years 74 (51%) 72 (49%)854 N.C. ARMITAGE et al.
Table II Subgroup analysis of the influence of DNA content on survival
5-year survival
Aneuploidl Test
Pathological stage tetraploid Diploid statistic P-value
A 15/21 (71%) 17/21 (81%) 0.6 0.43
B 40/86 (46%) 56/93 (60%) 3.6 0.058
C 11/67 (16%) 13/64 (20%) 0.1 0.71
D 2/37 (5%) 2/27 (7%) 0.0 0.96
Overall 68/211 (32%) 88/205 (43%) 5.0 0.02
Histological grade
Well differentiated 38/77 (49%) 37/73 (51%) 0.1 0.75
Mod. differentiated 26/109 (24%) 44/103 (43%) 8.3 0.004
Poor differentiated 4/25 (16%) 6/25 (24%) 0.07 0.78
Tumour site
Right side 19/45 (42%) 21/48 (44%) 0.01 0.91
Left side 24/72 (33%) 31/67 (46%) 1.8 0.17
Rectum 25/94 (26%) 36/90 (40%) 5.2 0.02
Local extension
Local extension 11/86 (13%) 18/87 (21%) 1.6 0.21
Mobile 57/123 (46%) 70/116 (60%) 5.2 0.02
Curability
Curative 54/103 (52%) 66/105 (63%) 2.3 0.12
Non-curative 14/108 (13%) 22/100 (22%) 2.7 0.10
Age
< 70 years 39/137 (28%) 51/133 (38%) 3.8 0.05
>70 years 29/74 (39%) 37/72 (51%) 1.4 0.23
Table III Multivariant analysis of prognostic factors
Stepwise logistic regression
Univariate analysis (before entry)
F value P-value
Sex 1.1 0.300
Age 0.6 0.429
Site 3.3 0.072
Stage 110.7 <0.001
Histological grade 18.3 <0.001
Curability 82.4 <0.001
Local extension 63.5 <0.001
DI 5.8 0.016
Multivariate analysis (after entry)
x2 improvement P-value
Stage 98.9 <0.001
Local extension 12.9 <0.001
DI 5.7 0.017
Site 3.6 0.056
Histological grade 3.4 0.066
Age
Site Not entered
Curability
in conjunction with the other factors, then only stage, local
tumour extension and DNA index remain as independent
variables.
Discussion
There have now been a number of reports supporting the
hypothesis that tumour cell DNA content (ploidy) is of
prognostic significance in colorectal cancer. However, few
have had sufficiently large numbers to allow adequate sub-
group analysis. We found no association between patho-
logical stage, histological grade or tumour site, and ploidy
status, which was consistent with our first report (Armitage
et al., 1985). Jones et al. (1988) and Jass et al. (1989) showed
a correlation with tumour stage but not with histological
grade. The reason for these differences is not clear. Some of
these differences may be in part due to differences in meth-
odology between series. We used 20gm paraffin sections to
be consistent with our previous work and have ourselves
changed to 30gm sections in a second, prospective series.
The thicker sections will tend to give a higher proportion of
aneuploid tumours. We used a single paraffin block to assess
ploidy status. It is well recognised that colorectal cancers are
heterogeneous with regard to ploidy (Quirke et al., 1985) and
that using a single block will underestimate the number of
tumours classified as aneuploid. However, Jones et al. (1988)
showed that a single block will correctly classify at least 75%
of tumours. If ploidy is to become a measure which is useful
clinically then it may well be that it is only practical to
measure ploidy in a single or limited number of blocks given
the number of tumours which would require measurement.
For this reason, as in our previous report, we used a single
representative section.
We found that 51% of tumours in our series were aneu-
ploid, which is lower than most other workers who have
reported 'aneuploidy rates' of between 51% and 82% (Scott
et al., 1987; Hiddeman et al., 1986) although most of the
larger series range between 51% and 65%. This lower aneu-
ploidy rate may be due to either or both ofthe reasons stated
above. It is interesting to note that in the series of 264
patients reported by Scott et al. (1987) a similar figure of
51% non-diploid tumours was found.
Another reason for differences in the reported series may
be related to the criteria by which tumours were classified as
diploid or aneuploid. We have used the criteria that 10% of
cells must be within the aneuploid peak, with a DNA index
between 1.1 and 1.9 and 15% between 1.9 and 2.1. This
agrees with the type 3 classification proposed by Jones et al.
(1988), which classified 58% of tumours as aneuploid in their
series and appeared to be the most discriminatory in terms of
survival.
We found that there was overall a survival advantage to
patients with diploid tumours but this was not as pro-
nounced as previously reported by us. Although the 5-year
survival of patients with DNA diploid tumours was very
similar at 44%, that of patients with DNA aneuploid tu-
mours was better in the larger series at 32% compared with
19% in our previous report. There was a greater proportion
of stage C tumours and stage A tumours with a smaller
proportion of stage B tumours in the larger group. Review-
ing the survival curves of patients with diploid and non-
diploid (aneuploid and tetraploid) tumours from various cen-
tres there is a general consistency in the survival advantage to
patients with diploid tumours (Scott et al., 1987; Quirke et
al., 1987; Jones et al., 1988; Jass et al., 1989). There are a
number of reports which show only a borderline or no
significant relation between DNA ploidy and prognosis
(Bauer et al., 1987; Schutte et al., 1987; Rognum et al., 1987).
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prognostic significance in a univariate analysis this was lost
in multivariant analysis (Jass et al., 1989). We found that
subdividing patients with non-diploid tumours into those
with tetraploid and/or aneuploid did not improve discrimina-
tion. This was an agreement with the findings of Jones et al.
(1988) where tetraploidy was defined in a similar way to this
series and also in agreement with Jass et al. (1989) where a
tetraploid peak had only to comprise of 10% of the nuclear
population. Despite the survival advantage for patients with
tetraploid tumours suggested by Quirke et al. (1987) we have
not found evidence to support this. We failed to find prog-
nostic value in the height of the aneuploid peak (percentage
ploidy) whereas Jones et al. (1988) and Scott et al. (1987)
found that the aneuploid peak size was of prognostic
significance. This may be due to differences in methodology
as outlined previously. It seems reasonable that more aggres-
sive tumours would have a greater proportion of aneuploid
cells or alternatively a smaller amount of stromal tissue. This
inconsistency needs to be further investigated.
We have confirmed that DNA content retained its prog-
nostic independence in the multivariant analysis in contra-
distinction to the report from Jass et al. (1989). However,
this may reflect the very detailed histopathological data
which was available on Jass's patients which may perhaps
not be available in all series. However, compared with path-
ological stage the contribution of DNA content is relatively
small. Kokal et al. (1989) found ploidy to be the most
important variable but this was in a selected group of
patients who had curative survery.
Turning to subgroup analysis, we found a survival advan-
tage in patients with diploid tumours in the following groups:
stage B tumours, moderately differentiated tumours, rectal
tumours and mobile tumours. This differs from other reports
where it has been shown that the survival advantage was for
stage C tumours (Schutte et al., 1987). The reason for this is
not clear. It would seem reasonable that if ploidy is regarded
as a marker of tumour aggressiveness and potential for
metastasis, that where these have already been shown, that is
in stage C and D tumours, demonstration of an increased
metastatic potential would add little to prognosis. Where
micrometastases have not been demonstrated then one may
expect a marker for such micrometastases to have prognostic
significance. The observation that the prognostic value of
ploidy was found in patients less than 70 years of age is less
easy to explain but it is of interest that the older patients
(greater than 70 years) tended to have a better survival. It
may be that more older patients were excluded because they
were not operated on or died postoperatively so that the
'survivors' were a selected group. We also found that ploidy
had a significant influence on survival in moderately differ-
entiated, mobile and rectal tumours. As far as moderately
differentiated tumours are concerned it is not surprising that
it is in this subgroup that the influence is found. Patients
with poorly or well differentiated tumours are likely to have
a poor or good outcome respectively and it is in the 'inter-
mediate' group that one would expect to see an influence of a
'new' prognostic factor. As far as rectal tumours are con-
cerned, Jass et al. (1989) and Quirke et al. (1987) studied.
rectal cancers exclusively and found a significant influence of
ploidy. Indeed, if preoperative knowledge of ploidy would
help plan adjuvant treatment then it is in rectal cancers one
would wish the maximum influence to be.
The multivariant analysis shows that stage, local extension
and ploidy remained independent prognostic factors. His-
tological grade and surgeons' assessment ofcurability, factors
which were highly significant in univariant analysis, lost
significance. It should be remembered that surgeons' assess-
ment ofcurability is mainly based on the presence or absence
ofdistant metastases and/or local extension. The former were
included in our staging system (stage D) and the latter was
included separately. Thus if these factors were already taken
into account, 'curability' had little further independent con-
tribution to prognosis. This is in contrast to Jones et al.
(1988), who found that 'curability' was the most powerful
prognostic variable but used Dukes's staging system without
a stage D and did not include assessment of local fixity
separately.
In conclusion, tumour cell DNA ploidy is an independent
factor in determining patient survival after resection for colo-
rectal cancer. It may be used in conjunction with other
factors to plan and to analyse the effects of adjuvant therapy.
Ths work was supported by the Cancer Research Campaign. We are
grateful to Miss Judith Wright, Mrs Ruth Marksman and Mr Alan
Street for excellent technical help and Mrs Patricia Robinson for
expert typing.
References
ARMITAGE, N.C., ROBINS, R.A., EVANS, D.F., TURNER, D.R., BALD-
WIN, R.W. & HARDCASTLE, J.D. (1985). The influence of tumour
cell DNA abnormalities on survival in colorectal cancer. Br. J.
Surg., 72, 828.
ASTLER, V.B. & COLLER, F.A. (1954). The prognostic significance of
direct extension of carcinoma of the colon and rectum. Ann.
Surg., 139, 846.
BAUER, K.D., LINCOLN, S.T., VERA-ROMAN, J.M. & 5 others (1987).
Prognostic implications of proliferative activity and DNA aneu-
ploidy in colonic adenocarcinomas. Lab. Invest., 57, 329.
BLENKINSOPP, W.K., STEWART-BROWN, S., BLESOVSKY, L. KEAR-
NEY, G. & FIELDING, L.P. (1981). Histopathology reporting in
bowel cancer. J. Clin. Pathol., 34, 509.
DUKES, C.E. (1932). The classification of cancer of the rectum. J.
Pathol. Bacteriol., 35, 323.
GOH, H.S., JASS, J.R., ATKIN, W.S., CUZICK, J. & NORTHOVER, J.M.
(1987). Value of flow cytometric determination of ploidy as a
guide to prognosis in operable rectal cancer: a multivariate
analysis. Int. J. Colorect. Dis., 2, 17.
HEDLEY, D.W., FRIEDLANDER, M.L, TAYLOR, I.W., RUGG, C.A. &
MUSGROVE, E.A. (1983). Method for analysis of cellular DNA
content in paraffin-embedded pathological material using flow
cytometry. J. Histochem. Cytochem., 31, 1333.
HIDDEMAN, W., SCHUMANN, J., ANDREEFF, M. & 6 others (1984).
Convention on nomendature for DNA cytometry. Cytometry, 5,
445.
HIDDEMAN, W., VON BASSEWITZ, D.B., KLEINEMEIER, H.J. & 5
others (1986). DNA stemline heterogeneity in colorectal cancer.
Cancer, 58, 258.
JASS, J.R., LOVE, S.B. & NORTHOVER, J.M.A. (1987). A new prognos-
tic classification of rectal cancer. Lancet, i, 1303.
JASS, J.R., MUKAWA, K., GOH, H.S., LOVE, S.B. & CAPELLARO, D.
(1989). Clinical importance of DNA content in rectal cancer
measured by flow cytometry. J. Clin. Pathol., 42, 254.
JONES, D.J., MOORE, M. & SCHOFIELD, P.F. (1988). Refining the
prognostic significance of DNA ploidy status in colorectal cancer.
A prospective flow cytometric study. Int. J. Cancer, 41, 206.
KIRKLIN, J.W., DOCKERTY, M.B. & WAUGH, J.M. (1949). The role
of the peritoneal reflection in the prognosis of carcinoma of the
rectum and sigmoid colon. Surg. Gynaecol. Obstet., 88, 326.
KOKAL, W.A., GARDINE, R.L., SHEIBANI, K. & 4 others (1989).
Tumour DNA content in resectable, primary colorectal cancer.
Ann. Surg., 209, 188.
PHILLIPS, R.K.S., HITTINGER, R., BLESOVSKY, L., FRY, J.S. & FIEL-
DING, L.P. (1984). Large bowel cancer: surgical pathology and its
relationship to survival. Br. J. Surg., 71, 604.
QUIRKE, P., DYSON, J.E., DIXON, M.F., BIRD, C.C. & JOSLIN, C.A.
(1985). Heterogeneity ofcolorectal adenocarcinomas evaluated by
flow cytometery and histopathology. Br. J. Cancer, 51, 99.
QUIRKE, P., DIXON, M.F., CLAYDEN, A.D. & 4 others (1987). Prog-
nostic significance of DNA aneuploidy and cell proliferation in
rectal adenocarcinomas. J. Pathol., 151, 285.
ROGNUM, T.O., THORUD, E. & LUND, E. (1987). Survival of large
bowel carcinoma patients with different DNA ploidy. Br. J.
Cancer, 56, 633.856 N.C. ARMITAGE et al.
SCHUTTE, B., REYNDERS, M.M.J., WIGGERS, T. & 4 others (1987).
Retrospective analysis of the prognostic significance of DNA
content and proliferative activity in large bowel carcinoma. Can-
cer Res., 47, 5494.
SCOTT, N.A., WIEAND, H.S., MOETREL, C.G., CHA, S.S., BEART, R.W.
& LIEBER, M.M. (1987). Colorectal cancer. Dukes' stage, tumor
site, pre-operative plasma CEA level and patient prognosis re-
lated to tumor DNA ploidy pattern. Arch. Surg., 122, 1375.
STOWER, M.J. & HARDCASTLE, J.D. (1985). The results of 1,115
patients with colorectal cancer treated over an 8 year period in a
single hospital. Eur. J. Surg. Oncol., 11, 119.
WOLLEY, R.C., SCHREIBER, K., KOSS, L.G., KARAS, M. & SHER-
MAN, A. (1982). DNA Distribution in human colon carcinomas
and its relationship to clinical behavior. J. Natl Cancer Inst., 69,
15.